- Details
- Ruchika Talwar interviews Benjamin Pockros about his published work in Urology Practice, which explores online tools to reduce financial toxicity for urology patients. Dr. Pockros presents a framework of four key tools: Medicare Part D Plan Finder, GoodRx, Mark Cuban Cost Plus Drugs Company, and Amazon Pharmacy. They discuss how each tool can be applied to different patient scenarios, emphasizing...
|
- Details
- Defining optimal therapeutic sequencing strategies in prostate cancer (PC) is challenging and may be assisted by artificial intelligence (AI)-based tools for an analysis of the medical literature. To demonstrate that INSIDE PC can help clinicians query the literature on therapeutic sequencing in PC and to develop previously unestablished practices for evaluating the outputs of AI-based support pla...
|
- Details
- Sam Chang interviews Surena Matin about a phase 1b trial evaluating FGFR3 inhibition in localized upper tract urothelial carcinoma (UTUC). Dr. Matin discusses the study's rationale, design, and results, highlighting the high prevalence of FGFR3 mutations in UTUC and the need for better management strategies. The trial demonstrates that FGFR inhibition with infigratinib is well-tolerated and rapidl...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the PI-CAI Challenge, an international study comparing artificial intelligence (AI) to radiologists in prostate cancer detection using MRI. The study develops and validates an AI system using a large dataset of prostate MRIs, comparing its performance to both study radiologists and real-world radiology readings. The AI system demonstrates superiority to stud...
|
- Details
- Pedro Barata interviews Yousef Zakharia about a phase 1/2 trial combining durvalumab and guadecitabine in metastatic kidney cancer. The study, conducted through the Big Ten Cancer Consortium, explores the potential synergy between hypomethylating agents and checkpoint inhibitors. Dr. Zakharia discusses the trial design, results, and biomarker findings. While the primary endpoint of objective respo...
|
- Details
- Ruchika Talwar interviews Logan Briggs about his study on urologic practice productivity using work relative value units (RVUs). The research, published in Urology Practice, analyzes data from over 6,700 urologists using the CMS database from 2017-2018. Dr. Briggs discusses findings, including that years in practice is the strongest predictor of productivity, peaking 34 years after medical school...
|
- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Ashish Kamat interviews Omar Alhalabi about research on small cell neuroendocrine carcinoma of the urinary tract. Dr. Alhalabi discusses the study's findings on prognostic factors for relapse in surgically resected cases. The research reveals that neoadjuvant chemotherapy benefits patients, while the persistence of small cell carcinoma at surgery is associated with a high risk of relapse. The stud...
|
- Details
- Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
|
- Details
- Ruchika Talwar hosts Daniel Triner to discuss a study on the management of lymph node-positive prostate cancer after radical prostatectomy. Using data from the Michigan Urological Surgery Improvement Collaborative (MUSIC), Dr. Triner's team analyzes treatment patterns for 666 patients. They find that approximately two-thirds of patients receive secondary treatment within 12 months, with variations...
|
